Datamatics Global Services surges on entering into strategic partnership with Alkermes
Datamatics Global Services is currently trading at Rs. 416.40, up by 2.70 points or 0.65% from its previous closing of Rs. 413.70 on the BSE.
The scrip opened at Rs. 414.05 and has touched a high and low of Rs. 431.35 and Rs. 392.00 respectively. So far 351164 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 431.35 on 03-May-2023 and a 52 week low of Rs. 233.80 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 431.35 and Rs. 302.00 respectively. The current market cap of the company is Rs. 2468.21 crore.
The promoters holding in the company stood at 70.91%, while Institutions and Non-Institutions held 2.69% and 26.39% respectively.
Datamatics Global Services has entered into a strategic partnership with Alkermes, a global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The partnership is focused on enhancing Alkermes’ patient support services for people prescribed Alkermes medicines.
As part of this collaboration, which began with a competitive procurement process during which Datamatics was selected; Datamatics has deployed a remote patient coordinator service staffed with a team of individuals with healthcare experience to support patients in accessing their medicines and reminding them of their appointments. Datamatics is also helping modernize existing systems and processes to enable the Alkermes’ Patient Access Services team to enhance the customer experience.
Datamatics Global Services provides intelligent solutions for data driven businesses to increase productivity and enhance the customer experience.